TENX
Tenax Therapeutics, Inc.
Biotechnology
Market Cap$69M
5Y Perf.-99.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TENX vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.6%
TENX vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TENX | ACAD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $69M | $3.86B |
| Revenue (TTM) | $0.00 | $1.10B |
| Net Income (TTM) | $-43M | $376M |
| Gross Margin | — | 91.5% |
| Operating Margin | — | 7.4% |
| Forward P/E | — | 50.9x |
| Total Debt | $0.00 | $52M |
| Cash & Equiv. | $95M | $178M |
TENX vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TENX
ACAD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tenax Therapeutics,… (TENX) | 100 | 0.5 | -99.5% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.4 | -54.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TENX vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TENX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
TENX
Tenax Therapeutics, Inc.
The Income Pick
TENX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.90
- EPS growth 96.3%
- Lower volatility, beta 0.90, current ratio 20.60x
Best for: income & stability and growth exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Long-Run Compounder
ACAD is the clearest fit if your priority is long-term compounding.
- -22.9% 10Y total return vs TENX's -100.0%
- 34.3% margin vs TENX's 2.0%
- 26.2% ROA vs TENX's -42.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TENX | 428.0% revenue growth vs ACAD's 11.9% |
| Quality / Margins | ACAD | 34.3% margin vs TENX's 2.0% |
| Stability / Safety | TENX | Beta 0.90 vs ACAD's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TENX | +109.2% vs ACAD's +52.4% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs TENX's -42.1% |
TENX vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2013
FY 2018
TENX vs ACAD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGTENX
TENXTenax Therapeutics, I…
1leads
ACADACADIA Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs TENXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD1/1
Valuation MetricsMultiples, price ratios, and targets
TENX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ACAD4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACAD and TENX operate at a comparable scale, with $1.1B and $0 in trailing revenue.
| Metric | TENXTenax Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.1B |
| EBITDAEarnings before interest/tax | -$43M | $96M |
| Net IncomeAfter-tax profit | -$43M | $376M |
| Free Cash FlowCash after capex | -$26M | $212M |
| Gross MarginGross profit ÷ Revenue | — | +91.5% |
| Operating MarginEBIT ÷ Revenue | — | +7.4% |
| Net MarginNet income ÷ Revenue | — | +34.3% |
| FCF MarginFCF ÷ Revenue | — | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -110.5% | -81.8% |
ACAD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
TENX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | TENXTenax Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| Market CapShares × price | $69M | $3.9B |
| Enterprise ValueMkt cap + debt − cash | -$26M | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -10.13x | 9.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 50.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 26.91x |
| Price / SalesMarket cap ÷ Revenue | — | 3.61x |
| Price / BookPrice ÷ Book value/share | 1.93x | 3.15x |
| Price / FCFMarket cap ÷ FCF | — | 36.74x |
TENX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-45 for TENX. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs TENX's 3/9, reflecting solid financial health.
| Metric | TENXTenax Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -45.0% | +35.6% |
| ROA (TTM)Return on assets | -42.1% | +26.2% |
| ROICReturn on invested capital | — | +10.0% |
| ROCEReturn on capital employed | -39.0% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | 0.04x |
| Net DebtTotal debt minus cash | -$95M | -$126M |
| Cash & Equiv.Liquid assets | $95M | $178M |
| Total DebtShort + long-term debt | $0 | $52M |
| Interest CoverageEBIT ÷ Interest expense | -847.57x | — |
ACAD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ACAD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,710 today (with dividends reinvested), compared to $35 for TENX. Over the past 12 months, TENX leads with a +109.2% total return vs ACAD's +52.4%. The 3-year compound annual growth rate (CAGR) favors ACAD at 1.5% vs TENX's -23.4% — a key indicator of consistent wealth creation.
| Metric | TENXTenax Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +5.4% | -13.7% |
| 1-Year ReturnPast 12 months | +109.2% | +52.4% |
| 3-Year ReturnCumulative with dividends | -55.1% | +4.7% |
| 5-Year ReturnCumulative with dividends | -99.6% | +7.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -22.9% |
| CAGR (3Y)Annualised 3-year return | -23.4% | +1.5% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TENX and ACAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
TENX is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than ACAD's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 81.1% from its 52-week high vs TENX's 63.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TENXTenax Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 1.26x |
| 52-Week HighHighest price in past year | $18.38 | $27.81 |
| 52-Week LowLowest price in past year | $5.34 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +63.4% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 38.4 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 520K | 1.8M |
Evenly matched — TENX and ACAD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TENXTenax Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $34.78 |
| # AnalystsCovering analysts | — | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TENX leads in 1 (Valuation Metrics). 1 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 3 of 6 categories
Loading custom metrics...
TENX vs ACAD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TENX or ACAD a better buy right now?
ACADIA Pharmaceuticals Inc.
(ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TENX or ACAD?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +7. 1%, compared to -99. 6% for Tenax Therapeutics, Inc. (TENX). Over 10 years, the gap is even starker: ACAD returned -22. 9% versus TENX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TENX or ACAD?
By beta (market sensitivity over 5 years), Tenax Therapeutics, Inc.
(TENX) is the lower-risk stock at 0. 90β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 40% more volatile than TENX relative to the S&P 500.
04Which is growing faster — TENX or ACAD?
On earnings-per-share growth, the picture is similar: Tenax Therapeutics, Inc.
grew EPS 96. 3% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TENX or ACAD?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 0% for Tenax Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus 0. 0% for TENX. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TENX or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TENX or ACAD better for a retirement portfolio?
For long-horizon retirement investors, Tenax Therapeutics, Inc.
(TENX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Both have compounded well over 10 years (TENX: -100. 0%, ACAD: -22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TENX and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TENX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.